info@seagull-health.com
SeagullHealth
search
Enasidenib(Idhifa)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Enasidenib(Idhifa) Instructions:Uses,Dosage, Side Effects
IDHIFA, with the generic name enasidenib, is an oral isocitrate dehydrogenase-2 (IDH2) enzyme inhibitor. It is formulated as film-coated tablets available in 50 mg and 100 mg strengths. The drug functions by targeting mutant IDH2 variants, leading to a reduction in the oncometabolite 2-hydroxyglutarate (2-HG) and promoting differentiation of myeloid cells. It is marketed by Bristol Myers Squibb Company.
IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved companion diagnostic test.
The recommended dosage is 100 mg taken orally once daily, with or without food.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
